Lessons from the implementation of the Australian 2016 prostate specific antigen testing clinical practice guidelines: a descriptive study.
Uloženo v:
| Název: | Lessons from the implementation of the Australian 2016 prostate specific antigen testing clinical practice guidelines: a descriptive study. |
|---|---|
| Autoři: | Heneka N; University of Southern Queensland, Toowoomba, Australia., Heathcote P; Brisbane Urology Clinic, Brisbane, Australia.; Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Queensland University of Technology, Brisbane, Australia., Malouf P; Public Health and Tropical Medicine, College of Medicine and Dentistry, James Cook University, Brisbane, Australia., Chambers SK; University of Southern Queensland, Toowoomba, Australia.; Australian Catholic University, Brisbane, Australia., Smith DP; The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia., Dunn J; University of Southern Queensland, Toowoomba, Australia.; Prostate Cancer Foundation of Australia, Sydney, Australia. |
| Zdroj: | ANZ journal of surgery [ANZ J Surg] 2025 Oct; Vol. 95 (10), pp. 2188-2196. Date of Electronic Publication: 2025 Apr 15. |
| Způsob vydávání: | Journal Article |
| Jazyk: | English |
| Informace o časopise: | Publisher: Wiley-Blackwell Publishing Asia Country of Publication: Australia NLM ID: 101086634 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1445-2197 (Electronic) Linking ISSN: 14451433 NLM ISO Abbreviation: ANZ J Surg Subsets: MEDLINE |
| Imprint Name(s): | Publication: Carlton, Victoria, Australia : Wiley-Blackwell Publishing Asia Original Publication: Carlton, Victoria, Australia : Blackwell Science Asia on behalf of the Royal Australasian College of Surgeons, c2001- |
| Výrazy ze slovníku MeSH: | Prostate-Specific Antigen*/blood , Prostatic Neoplasms*/diagnosis , Prostatic Neoplasms*/blood , Practice Guidelines as Topic* , Early Detection of Cancer*/standards , Early Detection of Cancer*/methods, Humans ; Male ; Australia/epidemiology ; Middle Aged ; Aged |
| Abstrakt: | Introduction: In 2025, prostate cancer is the most common cancer in Australia, regardless of gender, and is the second most common cause of cancer death despite the opportunities for cure. In 2016, Australian Clinical Practice Guidelines for Prostate Specific Antigen (PSA) testing were published to improve early detection and management of prostate cancer. This study reports on a public consultation into the implementation and impact of these guidelines on prostate cancer diagnosis and outcomes. Methods: Thematic analysis of responses from a public consultation conducted in accordance with best-practice guideline development processes. A national Call for Submissions, using a coordinated public notification strategy, was made, inviting consumers with an interest in PSA testing for prostate cancer to share their experiences via an online platform. Seven questions were posed to all respondents. Results: Consumers described the 2016 Guidelines as ineffective based on negative message framing, lack of uptake of the guidelines by key primary care groups, and low community awareness. Although a small number of men reported that they were able to access early detection and subsequent curative treatment, the majority of men reported missed opportunities for testing, resulting in diagnoses with late-stage disease. Suggestions for future successful implementation included a consumer companion to the guidelines, regular guideline review, a national education and awareness program, and targeted education for health professionals. Conclusions: Australia's future response to the growing burden of prostate cancer rests on key stakeholders across the health system to ensure alignment and compliance with updated Guidelines. Effective implementation of such guidelines in the future requires a well-resourced education and awareness program for both the lay and clinician communities, and consistency in adoption and practice across key medical groups. (© 2025 The Author(s). ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons.) |
| References: | Med J Aust. 1998 Jul 6;169(1):17-20. (PMID: 9695696) J Gen Intern Med. 2006 Feb;21 Suppl 2:S14-20. (PMID: 16637955) Urol Oncol. 2014 Jan;32(1):41.e23-30. (PMID: 23911680) Qual Saf Health Care. 2008 Aug;17(4):296-300. (PMID: 18678729) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Med J Aust. 2008 Sep 15;189(6):315-8. (PMID: 18803534) Int J Med Inform. 2016 May;89:55-62. (PMID: 26980359) Implement Sci. 2015 Feb 12;10:19. (PMID: 25884601) Am J Cardiovasc Drugs. 2021 Jul;21(4):419-433. (PMID: 33369718) JAMA. 1997 May 14;277(18):1452-5. (PMID: 9145717) Int J Technol Assess Health Care. 1998 Winter;14(1):47-70. (PMID: 9509795) Curr Urol. 2022 Dec;16(4):197-206. (PMID: 36714234) BMJ Open. 2015 Mar 17;5(3):e006367. (PMID: 25783420) Urol Oncol. 2025 Jan;43(1):49-53. (PMID: 39127529) Ann Intern Med. 2017 Oct 03;167(7):449-455. (PMID: 28869989) Arch Intern Med. 2009 Sep 28;169(17):1611-8. (PMID: 19786681) Implement Sci. 2022 Oct 29;17(1):75. (PMID: 36309746) Health Expect. 2024 Dec;27(6):e70092. (PMID: 39552111) Breast Cancer Res Treat. 2020 Jun;181(3):499-518. (PMID: 32378052) N Engl J Med. 2020 Apr 16;382(16):1557-1563. (PMID: 32294352) Ann Fam Med. 2013 Jul-Aug;11(4):306-14. (PMID: 23835816) Injury. 2023 May;54 Suppl 3:S26-S29. (PMID: 35135686) Urology. 1993 Jan;41(1):3-8. (PMID: 7678359) Aust J Gen Pract. 2023 Mar;52(3):91-95. (PMID: 36872083) Health Technol Assess. 2004 Feb;8(6):iii-iv, 1-72. (PMID: 14960256) Lancet. 2024 Apr 27;403(10437):1683-1722. (PMID: 38583453) J Natl Cancer Inst. 2015 Feb 06;107(4):. (PMID: 25663695) Int J Cancer. 2000 Jan 1;85(1):60-7. (PMID: 10585584) Implement Sci. 2020 Jun 3;15(1):41. (PMID: 32493348) PLoS One. 2022 Jan 27;17(1):e0261808. (PMID: 35085276) BJU Int. 2017 Aug;120(2):257-264. (PMID: 28139034) N Engl J Med. 1991 Apr 25;324(17):1156-61. (PMID: 1707140) BMJ. 1999 Feb 20;318(7182):527-30. (PMID: 10024268) |
| Contributed Indexing: | Keywords: early detection of cancer; primary health care; prostate‐specific antigen; prostatic neoplasms; public health |
| Substance Nomenclature: | EC 3.4.21.77 (Prostate-Specific Antigen) |
| Entry Date(s): | Date Created: 20250415 Date Completed: 20251030 Latest Revision: 20251101 |
| Update Code: | 20251101 |
| PubMed Central ID: | PMC12571940 |
| DOI: | 10.1111/ans.70136 |
| PMID: | 40231799 |
| Databáze: | MEDLINE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Introduction: In 2025, prostate cancer is the most common cancer in Australia, regardless of gender, and is the second most common cause of cancer death despite the opportunities for cure. In 2016, Australian Clinical Practice Guidelines for Prostate Specific Antigen (PSA) testing were published to improve early detection and management of prostate cancer. This study reports on a public consultation into the implementation and impact of these guidelines on prostate cancer diagnosis and outcomes.<br />Methods: Thematic analysis of responses from a public consultation conducted in accordance with best-practice guideline development processes. A national Call for Submissions, using a coordinated public notification strategy, was made, inviting consumers with an interest in PSA testing for prostate cancer to share their experiences via an online platform. Seven questions were posed to all respondents.<br />Results: Consumers described the 2016 Guidelines as ineffective based on negative message framing, lack of uptake of the guidelines by key primary care groups, and low community awareness. Although a small number of men reported that they were able to access early detection and subsequent curative treatment, the majority of men reported missed opportunities for testing, resulting in diagnoses with late-stage disease. Suggestions for future successful implementation included a consumer companion to the guidelines, regular guideline review, a national education and awareness program, and targeted education for health professionals.<br />Conclusions: Australia's future response to the growing burden of prostate cancer rests on key stakeholders across the health system to ensure alignment and compliance with updated Guidelines. Effective implementation of such guidelines in the future requires a well-resourced education and awareness program for both the lay and clinician communities, and consistency in adoption and practice across key medical groups.<br /> (© 2025 The Author(s). ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons.) |
|---|---|
| ISSN: | 1445-2197 |
| DOI: | 10.1111/ans.70136 |